Sensei Biotherapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview

Faeth Therapeutics,

17/03/2023 13:12

* Sensei Biotherapeutics Inc  SNSE.OQ   SNSE.O  is expected
to show no change in quarterly revenue when it reports 
results on March 20 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Sensei
Biotherapeutics
Inc is for a loss of 40 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Sensei
Biotherapeutics Inc is $5​, above​ its last closing price
of $1.39. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.37       -0.37      -0.44     Missed  -18.9
 Jun. 30 2022  -0.39       -0.39      -0.34     Beat    13.9
 Mar. 31 2022  -0.36       -0.35      -0.40     Missed  -14.3​
 Dec. 31 2021              -0.34      -0.30     Beat    11.8
 ​​Sep.                    -0.24      -0.32     Missed  -32
 30 2021                                                
 Jun. 30 2021  -0.28       -0.29      -0.32     Missed  -10.2​
 Mar. 31 2021  -0.30       -0.30      -0.42     Missed  -38.2
 Dec. 31 2020  -2.96       -2.96      -2.71     Beat    8.4
 This summary was machine generated March 17 at 13:12 GMT.  All
figures in US dollars  unless otherwise stated